Services

Translational Science

NDA Advisory Board

Regulatory Affairs

Pharmaco-
vigilance

High-Stakes Meetings

Health Technology Assessment

Spotlight

Brexit Impact

Are you ready?

More

More Spotlight Videos

News

Why should you engage early with regulators and HTA bodies?

14th May 2019

NDA’s Dr Mira Pavlovic-Ganascia and Claes Buxfeldt provide insight on what the expected outcomes of constructively engaging with regulators and HTA bodies could be.

More

The state of the Swedish orphan pipeline

7th May 2019

Business Sweden, together with SwedenBIO, have outlined the current state of Swedish orphan development in a new report. It describes a vibrant drug development landscape that is reflective of the global move towards orphan development and the strong emphasis on oncology.

More

Optimizing Value – Regulatory and Market Access Considerations

Welcome to NDA’s seminar on 21st May 08:30-13:00 in Solna, Sweden on Optimizing Value – Regulatory and Market Access Considerations.

More

4 ways that HTA will change under the new European regulation

6th May 2019

In this white paper NDA’s CEO, Johan Strömquist, discusses four ways that Health Technology Assessments will change under the new proposed European regulation.

More

In memoriam – Dr Eric Abadie

3rd May 2019

We were all greatly saddened to learn of the recent passing of our colleague and friend Dr Eric Abadie.

More

Webinar – Is an Early Development Strategy Really Needed?

25th April 2019

Join us on 16th May at 15:00 BST, 16:00 CEST, 10:00 EDT for this engaging webinar with Dr Niamh Kinsella, Biologics Expert, VP, Early Stage Development.

More

Observations of a market access expert

16th April 2019

An insightful interview with NDA’s Claes Buxfeldt, HTA Director, entitled “Observations of a market access expert” featured in Aprils edition of Pharmafocus.

More
More News
We have helped over 2,000 clients achieve success in the past
We have helped over 2,000 clients achieve success in the past

The leader in FDA Advisory Committee meeting preparation

“For innovative life science companies, NDA and PharmApprove are the best partners to help prepare to win at FDA Advisory Committees. Our pioneering approach — refined over 16 years experience and 150-plus projects — has helped more than 80 clients achieve success at these high-profile, high-stakes hearings.

NDA Intelligence

Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.

Members

A Career with NDA

Join NDA and get the chance to work with some of the leading minds in regulatory affairs, pharmacovigilance, health technology assessment and scientific communications on a variety of projects, clients and geographies.

Why work at NDA?

Our Locations

NDA Sweden

NDA Group AB
Johanneslundsv. 2
S-194 61 Upplands Väsby
Sweden

T. +46 (0)8 590 778 00
E. stockholm@ndareg.com

NDA France

7, rue Jobbé Duval,
75015 Paris,
France

T. +33 983 981 942
E. paris@ndareg.com

NDA Germany

Neumarkter Straße 18
D-81673 München
Germany

T. +49 (0)89 3585 4000
E. munich@ndareg.com

NDA Switzerland

Rigistrasse 5
8703 Erlenbach
Switzerland

T. +41 (0)78 951 9929
E. zurich@ndareg.com

NDA UK

Grove House
Guildford Road
Leatherhead,
Surrey KT22 9DF
United Kingdom

T. +44 (0) 1372 860 610
E. london@ndareg.com

NDA USA Massachusetts

NDA Regulatory Development Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
United States

T. +1 609 583 1990
E. usa@ndareg.com

NDA USA New Jersey

PharmApprove
200 Princeton South Corporate Center,
Suite 340
Ewing, NJ 08628
United States

T. +1 609 583 1990
E. usa@ndareg.com